Dr. Noaiseh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1000 E 101st Ter
Kansas City, MO 64131Phone+1 913-574-2438Fax+1 913-588-3987
Summary
- Dr. Ghaith Noaiseh is a rheumatologist in Kansas City, KS and is affiliated with UPMC Presbyterian. He received his medical degree from University of Tichreen Faculty of Medicine and has been in practice 15 years. He is experienced in sjogren's syndrome and clinical trials in sjogren's syndrome and sle.
Education & Training
University of Pennsylvania Health SystemFellowship, Rheumatology, 2010 - 2012
St Vincent Charity Medical CenterResidency, Internal Medicine, 2004 - 2007
University of Tichreen Faculty of MedicineClass of 2002
Certifications & Licensure
MO State Medical License 2019 - 2026
KS State Medical License 2019 - 2025
OH State Medical License 2004 - 2021
PA State Medical License 2010 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow American College of Rheumatology
Publications & Presentations
PubMed
- Recommendations for Aligned Nomenclature of Peripheral Nervous System Disorders Across Rheumatology and Neurology.Ghaith Noaiseh, Anahita Deboo, Jennifer K King, Arun Varadhachary, George Sarka
Arthritis & Rheumatology. 2024-11-03 - 3 citationsSafety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double...Benjamin A Fisher, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Hendrika Bootsma
Lancet. 2024-08-10 - 4 citationsCD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial.E William St Clair, Alan N Baer, Wan-Fai Ng, Ghaith Noaiseh, Chiara Baldini
Nature Medicine. 2024-06-01
Press Mentions
FcRn Blocker Nipocalimab Improves Disease Activity in Sjögren’s DiseaseNovember 25th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
